Global market expansion Minomic has commercial prostate cancer blood test MiCheck Prostate in the USA and Australia with plans to re-launch in other territories, presenting sales opportunities through multinational healthcare networks, distributors, and CLIA/high-complexity lab partnerships.

Healthcare cost benefits MiCheck Prostate reduces false positives by up to 50% and aims to minimize unnecessary biopsies, offering healthcare systems potential cost savings that can be highlighted in value-based selling to payors, hospitals, and clinics.

Clinical credibility High sensitivity and superior specificity supported by clinical studies and publications, enabling credible clinician-facing messaging, engagement with urology and oncology departments, and opportunities for academic collaborations.

Strategic partnerships Existing distribution through Sonic Healthcare and a Maryland CLIA lab presence indicate a channel-friendly path; explore additional lab networks, pathology groups, and government/public health collaborations to broaden adoption.

Growth levers Recent attention at events like Asia Summit on Global Health and ongoing R&D publications suggest momentum; leverage marketing automation and targeted outreach to biopharma, health systems, and regional distributors to accelerate uptake.